Literature DB >> 15000812

CCR5-Delta32 allele frequencies in Ashkenazi Jews.

G Lucotte1, P Smets.   

Abstract

This study was carried out to determine the 32-bp deletion allele frequencies in the CCR5 gene (CCR5-Delta32) in various populations of Jews of eastern European origin (Ashkenazi Jews). The total population sample (n = 351) represented Ashkenazi Jews originating from seven geographic groups in Europe. The overall frequency of the CCR5-Delta32 allele was elevated (13.7%), although some important differences in frequencies occurred among the seven countries included in the survey; the frequency was highest (25.9%) in those of Lithuanian origin. There is an apparent trend (r = 0.74) involving a lowering of the Delta32 allele frequencies moving from north to south in the seven populations tested. The Delta32 frequencies obtained were compared to those already published for non-Jewish populations inhabiting the same countries and the differences in frequencies were not significant, with the exception of Lithuania (chi(2) = 2.20, p < 0.03). Founder effect and genetic drift are proposed to explain the elevated values observed in Ashkenazi Jews and those originating from Lithuania.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15000812     DOI: 10.1089/109065703322783716

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  3 in total

1.  Genetic variants associated with susceptibility of Ashkenazi Jews to West Nile virus infection.

Authors:  N Danial-Farran; S Eghbaria; N Schwartz; Z Kra-Oz; N Bisharat
Journal:  Epidemiol Infect       Date:  2014-05-27       Impact factor: 4.434

2.  The geographic spread of the CCR5 Delta32 HIV-resistance allele.

Authors:  John Novembre; Alison P Galvani; Montgomery Slatkin
Journal:  PLoS Biol       Date:  2005-10-18       Impact factor: 8.029

3.  Could FIV zoonosis responsible of the breakdown of the pathocenosis which has reduced the European CCR5-Delta32 allele frequencies?

Authors:  Eric Faure
Journal:  Virol J       Date:  2008-10-16       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.